Zivo Bioscience

Zivo Bioscience, Inc. engages in the study, development, and commercialization of natural nutritional compounds and bioactive molecules. It offers proprietary algae strain, extracts and supernatants, and bioactive compounds. The company was founded by Howard R. Baer on March 28, 1983 and is headquartered in Keego Harbor, MI.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zivo Bioscience, Inc. engages in the study, development, and commercialization of natural nutritional compounds and bioactive molecules. It offers proprietary algae strain, extracts and supernatants, and bioactive compounds. The company was founded by Howard R. Baer on March 28, 1983 and is headquartered in Bloomfield Hills, MI.

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today provided an update on activities related to licensing its product targeting coccidiosis in broiler chickens. Following the announcement in August 2024 of positive results from a 42-day coccidiosis study, the Company has been engaged in discussions.

ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from a study conducted in collaboration with the University of Delaware that evaluated the potential of ZIVO's proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among po.

ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from its latest 42-day study with its product targeting coccidiosis in broiler chickens. The study, which was conducted in collaboration with a major global animal health company and replicated real-world poultry production env.

ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (NASDAQ: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day confirmatory study targeting coccidiosis in collaboration with a major global animal health company. This new study aims to further validate the efficacy of ZIVO's non-antibiotic, immune-modulating product designed.

Major Global Animal Health Company Launches 42-Day Confirmatory Study with ZIVO Bioscience's Coccidiosis Treatment in Broiler Chickens

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces additional findings from its 42-day coccidiosis challenge study that demonstrate the product's positive impact on the cost of broiler production as an alternative to commonly-used antibiotics. ZIVO's product candidate for use in pou.

ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces it has uplisted the trading of shares of its common stock from the OTC® Pink Market to the OTCQB® Venture Market (OTCQB), effective as of the opening of trading on Friday, January 26, 2024. Following this uplisting, ZIVO Bioscience.

ZIVO Bioscience Announces Uplisting to OTCQB Market

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTC PINK: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive efficacy results following its recent 42-day coccidiosis challenge study further demonstrating the effectiveness of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO's product candidate for.

ZIVO Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day study to further validate the efficacy of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO is developing a product candidate for use in poultry feed that is designed to boos.

ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that the Board of Directors of the Company approved a 1-for-6 reverse stock split (the “Reverse Stock Split”) of its shares of common stock, par value $0.001 (the “Common Stock”) effective at 5:00 p.m. ET on October 26, 2023 (the “Effective.

ZIVO Bioscience Announces Reverse Stock Split

BLOOMFIELD HILLS, Mich, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces that management will deliver a company presentation and will hold investor meetings at the 8 th Annual Dawson James Small Cap Growth Conference being held Thursday, October 12, 2023 at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Fla.

ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive results from a month-long coccidiosis trial in broiler chickens that was conducted by an independent veterinary research provider. The study evaluating the Company's novel immune-modulating biologic for treating coccidiosi.

Trial Results Confirm Efficacy of ZIVO Bioscience's Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (“ZIVO” or the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today provided an update on the commercialization of Zivolife, its proprietary algal biomass as a food or food ingredient. Following strong initial sales, ZWorldwide, an independent distributor with exclusive rights to the Zivolife.

ZIVO Announces Commitment by ZWorldwide to Purchase all Zivolife™ Algal Biomass Product Produced Over the Next 18 Months

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (“ZIVO” or the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the commercialization of its proprietary algal biomass as a food or food ingredient. ZIVO has engaged an independent distributor, ZWorldwide, Inc., who will launch the product, branded ZivolifeTM, with an initial focus on.

ZIVO Commences Sales of its Proprietary Algal Biomass as Human Food

AppHarvest

Black Rifle Coffee

Estee Lauder

Smart for Life Inc

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.

Top 5 Defensive Stocks Which Could Rescue Your Portfolio For July

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,498,130 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Na.

ZIVO Bioscience Announces Pricing of $4.0 Million Registered Direct Offering Priced At-The-Market

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced it has received an updated dossier from an independent scientific review panel reconfirming the Company's “Generally Recognized As Safe” (GRAS) designation for its proprietary algal biomass to be marketed and used as an ingre.

ZIVO's GRAS Designation Reaffirmed for Proprietary Algal Biomass Product as a Human Food Ingredient

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced a $1 million unsecured six-month loan from its Chairman, Chief Executive Officer, and President, John Payne.

ZIVO Bioscience Receives $1 Million Bridge Financing

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced the results of a four-month study performed by a third party on behalf of a potential partner company, which included a 42-day coccidiosis trial in broiler chickens.

ZIVO Bioscience Announces Results of Study with its Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens

ZIVO Bioscience Announces Plans for a New Streamlined, Focused Corporate Structure and Establishes the ZIVOLife Agtech Business

Lazydays

Protara Therapeutics Inc

TRACON Pharmaceuticals

Mountain Crest Acquisition Corp II

L. B. Foster

LINKBANCORP Inc

Liquidia Technologies Inc

Larimar Therapeutics Inc

Macerich

MFA Financial

B. Riley Financial

TransCode Therapeutics

Tilly's

In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.

Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today issued the following letter to shareholders from its Chairman, President and Chief Executive Officer, John Payne. To My Fellow Shareholders, Having served as a member of the Board of Directors of ZIVO Bioscience since 2013 and as Chairman since 2019,

ZIVO Bioscience CEO Issues Letter to Shareholders

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces receipt of a letter from the U.S. Department of Agriculture's (USDA) Center for Veterinary Biologics (CVB) affirming that the agency has claimed jurisdiction for reviewing the Company's novel immune-modulating biologic for treating

ZIVO Reports that USDA Claims Regulatory Jurisdiction for New Coccidiosis Treatment

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that, effective today, June 27, 2022, it has joined the Russell Microcap® Index (^RUMIC) as a result of the 2022 Russell indexes annual reconstitution. Membership in the Russell Microcap® Index, which remains in place for one

Zivo Bioscience Joins Russell Microcap® Index

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that it received a Notice from Nasdaq that the Company has regained compliance of Nasdaq Listing Rule 5250(c)(1). On April 19, 2022, the Company received a standard notice of noncompliance from Nasdaq indicating that, as a re

Zivo Bioscience Regains Compliance Following Receipt of Noncompliance Notice from Nasdaq

KEEGO HARBOR, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (“ZIVO” or the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces that Chairman of the Board John B. Payne has been named President and Chief Executive Officer of the Company. Mr. Payne succeeds Andrew A. Dahl. “I am honored to assume the executive leadership of ZIVO B

ZIVO Bioscience Names Chairman John B. Payne as President and CEO

News for Zivo Bioscience Stock (ZIVO)